Improving Access to Care for Veterans With Memory Loss
This study is testing a new way to help Veterans with memory loss get care faster. It's called the ADRD Care Delivery Protocol, and it uses telehealth and special tests to quickly check if you qualify for certain Alzheimer's disease treatments. The study is looking for Veterans aged 18 and older who have mild memory problems or early Alzheimer's disease, are enrolled in VA care, and live at home. The main goal is to see how quickly participants can be determined eligible for monoclonal antibody therapy and how quickly they can receive their first infusion, both measured up to 12 months. The study is currently enrolling about 30 participants.
- Study design
- This is a randomized controlled trial involving about 30 participants. It is testing an intervention called the ADRD Care Delivery Protocol.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 12 months to measure the time to eligibility determination and time to initial infusion.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Improving Access to Care for Veterans With Memory Loss
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Time to Eligibility DeterminationFrom date of randomization until the date of determination of eligibility for monoclonal antibody therapy, assessed up to 12 months.
Compare the number of days from randomization to the determination of eligibility for monoclonal antibody therapy for both the intervention and usual care groups, assessed up to 12 months.
- Time to Initial InfusionFrom date of randomization until the date of first infusion, assessed up to 12 months.
Compare the number of days from the date of randomization to the initial infusion of monoclonal antibody therapy for both the intervention and usual care groups, assessed up to 12 months.